These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

783 related items for PubMed ID: 17521292

  • 21. PPAR and Pain.
    Maeda T, Kishioka S.
    Int Rev Neurobiol; 2009; 85():165-77. PubMed ID: 19607969
    [Abstract] [Full Text] [Related]

  • 22. Evolution of peroxisome proliferator-activated receptor agonists.
    Chang F, Jaber LA, Berlie HD, O'Connell MB.
    Ann Pharmacother; 2007 Jun; 41(6):973-83. PubMed ID: 17519293
    [Abstract] [Full Text] [Related]

  • 23. Molecular recognition of docosahexaenoic acid by peroxisome proliferator-activated receptors and retinoid-X receptor alpha.
    Gani OA, Sylte I.
    J Mol Graph Model; 2008 Sep; 27(2):217-24. PubMed ID: 18547851
    [Abstract] [Full Text] [Related]

  • 24. Peroxisome proliferator-activated receptors and acute lung injury.
    Cuzzocrea S.
    Curr Opin Pharmacol; 2006 Jun; 6(3):263-70. PubMed ID: 16580256
    [Abstract] [Full Text] [Related]

  • 25. Peroxisome proliferator activated receptor ligands for the treatment of insulin resistance.
    Patsouris D, Müller M, Kersten S.
    Curr Opin Investig Drugs; 2004 Oct; 5(10):1045-50. PubMed ID: 15535425
    [Abstract] [Full Text] [Related]

  • 26. Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors.
    Lee TI, Kao YH, Chen YC, Chen YJ.
    Eur J Clin Invest; 2009 Jan; 39(1):23-30. PubMed ID: 19067734
    [Abstract] [Full Text] [Related]

  • 27. Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease?
    Denning GM, Stoll LL.
    Pediatr Pulmonol; 2006 Jan; 41(1):23-34. PubMed ID: 16267824
    [Abstract] [Full Text] [Related]

  • 28. A PPARs cross-talk concertedly commits C6 glioma cells to oligodendrocytes and induces enzymes involved in myelin synthesis.
    Leisewitz AV, Urrutia CR, Martinez GR, Loyola G, Bronfman M.
    J Cell Physiol; 2008 Nov; 217(2):367-76. PubMed ID: 18543250
    [Abstract] [Full Text] [Related]

  • 29. PPARs and their metabolic modulation: new mechanisms for transcriptional regulation?
    Ahmed W, Ziouzenkova O, Brown J, Devchand P, Francis S, Kadakia M, Kanda T, Orasanu G, Sharlach M, Zandbergen F, Plutzky J.
    J Intern Med; 2007 Aug; 262(2):184-98. PubMed ID: 17645586
    [Abstract] [Full Text] [Related]

  • 30. PPARs and the kidney in metabolic syndrome.
    Ruan X, Zheng F, Guan Y.
    Am J Physiol Renal Physiol; 2008 May; 294(5):F1032-47. PubMed ID: 18234957
    [Abstract] [Full Text] [Related]

  • 31. Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury.
    Cuzzocrea S.
    Vascul Pharmacol; 2004 Jul; 41(6):187-95. PubMed ID: 15653094
    [Abstract] [Full Text] [Related]

  • 32. [Peroxisome proliferator-activated receptors (PPAR) in pathophysiology of the circulatory system and prospective use of agonists of these receptors in therapy].
    Bełtowski J, Wójcicka G, Jamroz A.
    Postepy Hig Med Dosw; 2003 Jul; 57(2):199-217. PubMed ID: 12866356
    [Abstract] [Full Text] [Related]

  • 33. Nuclear receptors of the peroxisome proliferator-activated receptor (PPAR) family in gestational diabetes: from animal models to clinical trials.
    Arck P, Toth B, Pestka A, Jeschke U.
    Biol Reprod; 2010 Aug 01; 83(2):168-76. PubMed ID: 20427759
    [Abstract] [Full Text] [Related]

  • 34. PPARs: therapeutic targets for metabolic disease.
    Berger JP, Akiyama TE, Meinke PT.
    Trends Pharmacol Sci; 2005 May 01; 26(5):244-51. PubMed ID: 15860371
    [Abstract] [Full Text] [Related]

  • 35. PPAR ligands: are they potential agents for cardiovascular disorders?
    Balakumar P, Rose M, Singh M.
    Pharmacology; 2007 May 01; 80(1):1-10. PubMed ID: 17496434
    [Abstract] [Full Text] [Related]

  • 36. Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation.
    Wei ZL, Petukhov PA, Bizik F, Teixeira JC, Mercola M, Volpe EA, Glazer RI, Willson TM, Kozikowski AP.
    J Am Chem Soc; 2004 Dec 29; 126(51):16714-5. PubMed ID: 15612696
    [Abstract] [Full Text] [Related]

  • 37. [Nuclear receptors PPAR as a drug target in metabolic disorders].
    Stolarczyk M, Gutman W, Derlacz RA.
    Postepy Biochem; 2011 Dec 29; 57(2):207-14. PubMed ID: 21913422
    [Abstract] [Full Text] [Related]

  • 38. Kinase signaling cascades that modulate peroxisome proliferator-activated receptors.
    Gelman L, Michalik L, Desvergne B, Wahli W.
    Curr Opin Cell Biol; 2005 Apr 29; 17(2):216-22. PubMed ID: 15780600
    [Abstract] [Full Text] [Related]

  • 39. [PPARs: structure, mechanisms of action and control. Note I].
    Filip-Ciubotaru F, Foia L, Manciuc C, Grigore C.
    Rev Med Chir Soc Med Nat Iasi; 2011 Apr 29; 115(2):477-84. PubMed ID: 21870744
    [Abstract] [Full Text] [Related]

  • 40. The toxicology of ligands for peroxisome proliferator-activated receptors (PPAR).
    Peraza MA, Burdick AD, Marin HE, Gonzalez FJ, Peters JM.
    Toxicol Sci; 2006 Apr 29; 90(2):269-95. PubMed ID: 16322072
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.